SolarEdge Technologies reported on its convertible note issuances from 2024, including the use of $28.3 million for capped call transactions to mitigate potential dilution. The filing details the accounting treatment of vendor non-trade receivables and confirms that antidilutive contracts are excluded from diluted EPS calculations.
Aemetis reported a significant revenue increase to $88.2 million for Q3 2026, achieving a net income of $5.2 million compared to a net loss of $23.7 million in the prior year period. The company is expanding its California Dairy Renewable Natural Gas operations, recently placing two new anaerobic digesters into service and increasing its biogas collection pipeline network.
Dogwood Therapeutics reported third quarter 2026 financial results, highlighting the completion of its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain with top-line results expected in November 2026. The company also closed a $5 million private placement with Sealbond Limited to fund Phase 3 preparatory activities, extending its cash runway into the first quarter of 2027.
Term
3 months
“With results from the recently completed Phase 2b CINP study to be reported in November, we believe that if successful, Halneuron® could represent the first new therapeutic agent for millions of CINP patients in the US and tens of millions of CINP patients across the globe.”
Greg Duncan, Chief Executive Officer of Dogwood Therapeutics
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on hematologic diseases, reporting as a large accelerated filer with 45,540,842 shares of common stock outstanding as of October 29, 2026. The company continues to incur significant net losses, has no products approved for commercial sale, and anticipates the need for substantial additional funding to support its clinical development programs, including bitopertin.
Oncor reported Q3 2026 net income of $572 million, a significant increase from $380 million in the prior year, driven by new base rates and higher customer consumption due to warmer weather. The company deployed $6.3 billion in capital through the first nine months of the year and remains on track for a record $9.0 billion annual capital investment plan to support Texas' growing energy infrastructure needs.
“Texas’ continued economic growth depends on having the electric infrastructure in place to reliably serve its communities and businesses. I want to thank the Oncor team for their continued commitment to safely and reliably serving our customers and for the important work underway to help strengthen the grid for Texas’ future. We look forward to working with lawmakers, regulators, landowners, and other stakeholders across Texas to advance the infrastructure needed to meet the state’s growing energy needs.”
Playtika Holding Corp. reported revenues of $673.8 million for the third quarter of 2026, nearly flat compared to the prior year. While income from operations for the quarter increased to $116.2 million, the nine-month performance showed a decline in operating income from $275.9 million in 2025 to $201.2 million in 2026, primarily driven by higher general and administrative expenses.
For the nine months ended September 30, 2026, MACERICH CO reported a net loss attributable to the company of $80.2 million, an improvement from the $178.4 million loss in the prior year period. Total revenues remained relatively flat at $751.3 million, while the company significantly strengthened its cash position to $560.8 million and reduced mortgage notes payable by approximately $659 million.
ScanSource reported net sales of $962.3 million for the quarter ended September 30, 2026, a significant increase from $739.7 million in the prior year, though net income decreased to $8.7 million from $19.9 million. The company's balance sheet reflects a substantial increase in goodwill and intangible assets, alongside new borrowings of $231.9 million under its revolving credit facility.
Disc Medicine reported Q3 2026 financial results and provided a corporate update, highlighting the successful Phase 3 APOLLO trial of bitopertin which met all primary and secondary endpoints. The company plans to resubmit its NDA for bitopertin by year-end 2026 and recently strengthened its balance sheet with a $486 million public offering in October, extending its cash runway into 2030.
“In our first pivotal trial readout as a company, APOLLO delivered strong and compelling evidence of the potential clinical benefit of bitopertin for patients with EPP. We look forward to engaging with regulators with the goal of bringing an important, innovative medicine to this community as efficiently as possible.”
John Quisel, J.D., Ph.D., President and Chief Executive Officer
“Alongside our anticipated end-of-Phase 2 FDA meeting for selcodebart in anemia of myelofibrosis in the fourth quarter and a strengthened balance sheet, we are well positioned to support the anticipated launch of bitopertin and advance two additional programs toward pivotal-stage development in 2027.”
John Quisel, J.D., Ph.D., President and Chief Executive Officer
Perma-Fix Environmental Services reported Q3 2026 financial results, highlighting a 39% sequential revenue increase and a 25% growth in treatment backlog to $19.6 million. The company noted increased activity at its Perma-Fix Northwest facility related to the Hanford DFLAW program and improved margins in its Services Segment.
Term
3 months ended September 30, 2026
“Our third quarter results reflect meaningful improvement over the first half of the year. Revenue increased 39% sequentially from second quarter of 2026, consolidated gross profit returned to positive territory and our net loss decreased from the second quarter.”
MDU Resources reported third quarter 2026 net income of $14.0 million, or $0.07 per share, while reaffirming its full-year earnings guidance. The company also announced a positive final investment decision for the Bakken East Pipeline, a major infrastructure project with an estimated capital investment of $2.8 billion to $3.1 billion.
“We continued to execute our CORE strategy during the third quarter, with strong performance from our electric utility while advancing significant investments that are designed to support growing energy needs and long-term value creation.”
Nicole A. Kivisto, president and CEO of MDU Resources
“Our employees are the foundation of our ability to safely and reliably serve customers while advancing these growth opportunities. They operate and maintain the systems that serve our customers while working to meet the evolving energy needs of our communities.”
Nicole A. Kivisto, president and CEO of MDU Resources
ScanSource reported Q1 fiscal 2027 financial results with net sales increasing 30.1% year-over-year to $962.3 million, driven by strong demand and the acquisition of MicroAge. Despite top-line growth, GAAP diluted EPS fell to $0.42 from $0.89 in the prior year, impacted by sales mix and higher bad debt expense in Brazil.
Term
Q1 2027
“Top-line demand was strong this quarter, and we grew net sales and gross profit in both segments. We’re executing our strategy and expanding our total addressable market. In September, we closed the MicroAge acquisition, which enhances our solution capabilities and aligns with our 3-year strategic goals.”
CION Investment Corp reported Q3 2026 financial results, including net investment income of $0.25 per share and a net asset value of $13.20 per share. The company also declared base distributions totaling $0.25 per share for the first quarter of 2027 and successfully completed a deleveraging strategy by repaying its JPM Credit Facility and Series A Senior Unsecured Notes.
Investors Title Company reported Q3 2026 net income of $9.4 million on revenues of $81.9 million, which grew 12.1% year-over-year. The revenue growth was driven by higher real estate transaction volumes and title insurance premiums, though earnings were impacted by net investment losses and higher claims provisions.
Term
Q3 2026
“We are pleased with the growth in title insurance revenues and continued ongoing initiatives. While higher claims experience and investment-related volatility decreased quarterly earnings, our underlying business continued to perform well, contributing to solid year-to-date results.”
MarketWise reported Q3 2026 financial results with billings increasing 27% year-over-year to $80.7 million and net income of $15.1 million. The company reaffirmed its full-year 2026 billings target of $330 million and cash flow from operations target of $50 million while maintaining its $1.80 per share annual dividend target.
Term
Q3 2026
“The operational momentum and strong growth continued into the third quarter as Q3 Billings increased 27% year over year due to higher customer acquisition in Q1 and Q2, improved customer retention, and strong conversion of our higher priced products”
Dr. David Eifrig, Chief Executive Officer
“Our performance for the year is largely playing out as we expected. As previously mentioned, for the first and second quarters, we meaningfully increased investment in customer acquisition. This opportunistic marketing investment resulted in a strong increase in Paid Subscribers during the first half of the year.”
MarketWise, Inc. reported total net revenue of $80.1 million for the third quarter of 2026, a slight decrease from $81.3 million in the prior year period. Net income for the quarter was $15.1 million, down from $17.9 million, while year-to-date income from operations saw a significant decline from $49.4 million in 2025 to $10.5 million in 2026 due to increased sales and marketing and general and administrative expenses.
For the nine months ended September 30, 2026, NeoNc Technologies reported a net loss of $27.5 million, an improvement from the $46.6 million loss in the prior year period. The company significantly strengthened its cash position to $6.2 million through various private placements and equity offerings, though it continues to operate with a stockholders' deficit of $13.2 million.
Loar Holdings Inc. reported net sales of $176.2 million for the third quarter of 2026, a significant increase from $126.8 million in the prior year period. Despite higher operating income, net income for the quarter decreased to $19.6 million from $27.6 million year-over-year, primarily driven by a substantial increase in interest expense and a higher income tax provision.
Aemetis reported Q3 2026 financial results with revenue growing 49% year-over-year to $88.2 million and net income of $5.2 million. Results were significantly bolstered by $24.7 million in Section 45Z production tax credits following a favorable update to the U.S. Department of Energy's emission model for dairy RNG.
“We are pleased to report third quarter net income of $5.2 million and the continued growth of Aemetis Biogas production, supported by the updated calculation of emission rates under 45Z.”
Eric McAfee, Chairman and CEO of Aemetis
“Revenues during the third quarter of 2026 were $88.2 million, including $24.7 million of Section 45Z production tax credits. These results reflect strong execution by our California Ethanol and Dairy Renewable Natural Gas segments.”
Novavax reported total revenue of $68.3 million for the third quarter of 2026, a slight decrease from $70.4 million in the prior year, while net loss narrowed significantly to $31.4 million compared to $202.4 million. For the nine-month period, the company experienced a net loss of $94.3 million, a sharp reversal from the $422.8 million net income recorded in the same period of 2025, primarily due to a substantial drop in product sales and licensing revenue.
For the thirty-nine weeks ended September 27, 2026, Holley Inc. reported net sales of $460.9 million and net income of $12.7 million, remaining relatively flat compared to the prior year. The company experienced a significant $28.6 million loss on the sale of assets during the period, which was offset by lower interest expenses and favorable fair value adjustments on liabilities.
Vivmark Residential reported its first quarterly results following the August 2026 merger of equals between Equity Residential and AvalonBay Communities. The company increased its expected annual net run-rate operating synergies to $135 million and lowered its total expected merger-related costs to $725 million.
Term
Q3 2026
“In our first quarter as Vivmark, we delivered operating results ahead of plan and are increasing our expectations for synergies and upfront value creation. In addition to these strong financial results, we are advancing our priorities of using our scale and capabilities to deliver more responsive service, better digital tools and greater convenience for our residents.”
Holley Inc. reported third quarter 2026 net sales of $141.6 million, representing 2.3% growth year-over-year, and achieved its year-end leverage target of 3.5x a quarter early. The company reduced its debt by $25 million during the quarter and reported net income of $7.8 million compared to a net loss in the prior year period.
Term
Q3 2026
“Our third quarter results reflect the continued strength of our core business, which has now grown in six of the last seven quarters, and the progress we are making against our strategic priorities. Our teams delivered that performance in a moderating macroeconomic environment, which makes their execution even more impressive, and I am proud of what they accomplished.”
Matthew Stevenson, President and Chief Executive Officer
“The third quarter demonstrated continued progress across sales growth, profitability, cash generation, and balance sheet strength. We delivered year-over-year Adjusted EBITDA growth of 8.6% and generated $8.8 million of free cash flow, a $3.3 million improvement year-over-year, reflecting our continued focus on operational execution and financial discipline.”
National Fuel Gas Company reported fiscal year 2026 GAAP earnings of $7.02 per share and adjusted earnings of $7.55 per share, a 9% increase year-over-year. The company also announced a strategic plan to separate its Integrated Upstream and Gathering business into a standalone publicly traded company named Seneca Resources by the second half of 2027.
Term
FY2026
“Fiscal 2026 was an excellent year for National Fuel. The Company grew adjusted earnings per share 9% year over year, while generating significant free cash flow and continuing to return cash to our shareholders through our dividend, which we’ve paid for the 124th consecutive year.”
David P. Bauer, President and Chief Executive Officer
“As we look forward, National Fuel is entering an exciting next chapter. The long-term outlook for each of our businesses is strong. With the closing of our Ohio gas utility acquisition and our announced plan to separate our Integrated Upstream and Gathering business, we are well positioned to establish two scaled, financially sound publicly traded natural gas businesses.”
David P. Bauer, President and Chief Executive Officer
White Mountains reported total revenues of $2.0 billion for the first nine months of 2026, down from $2.1 billion in the prior year, primarily due to investment losses in the third quarter. The company completed the sale of the Bamboo Group during the period and saw significant growth in its Specialty Insurance Distribution and WTM Partners segments through acquisitions.
Priority Technology Holdings reported Q3 2026 revenue of $268.6 million, an 11.3% increase year-over-year, though net income fell 55.7% to $12.2 million. The company noted its pending go-private merger with WD Capital Partners for $8.05 per share is expected to close in the first half of 2027. Due to the pending acquisition, the company has suspended providing forward-looking guidance and will no longer host earnings conference calls.
IMAX Corporation reported record-breaking third quarter 2026 financial results, achieving its best quarterly performance in company history driven by the success of Christopher Nolan’s 'The Odyssey'. The company saw revenue surge 64% to $175 million and global box office reach a record $712 million, while net income per diluted share rose 430% to $1.96.
Term
Q3 2026
“What IMAX achieved goes beyond simply a ‘great quarter’ and transcends the many records we shattered in the period. What we believe we are witnessing is an awakening to the power and potential of our platform to impact global culture, unlock new commercial opportunities, and inspire a new level of demand and awe in audiences around the world.”
Rich Gelfond, CEO of IMAX Corporation
“Christopher Nolan’s The Odyssey is a historic cinematic achievement crafted entirely with IMAX technology and its record-breaking success marks a new era of opportunity for our company. The record margins we generated in the quarter demonstrate the unique strength of our model, and the growing value of scarce events and experiences in an increasingly A.I.-driven world underscore a powerful opportunity for our business, as we look ahead to a remarkably strong slate over the next several years.”
Loar Holdings reported record Q3 2026 net sales of $176.2 million, a 39% increase year-over-year, driven by 15.8% organic growth and recent acquisitions. While Adjusted EBITDA rose 46.5% to $71.9 million, net income declined to $19.6 million due to higher interest and tax expenses. The company also raised its financial outlook for both full-year 2026 and 2027.
“Our record results in the third quarter of 2026 reflects our continued successful execution along all our value drivers. Most noteworthy our operating cash flow for the quarter after being reduced by our capital expenditures were a record for the quarter improving 46% over the comparative previous year period.”
Dirkson Charles, Loar Holdings Chief Executive Officer and Executive Co-Chairman of the Board of Directors
CRA International reported fiscal year-to-date 2026 revenues of $626.7 million, a 13% increase over the prior year, though net income decreased slightly to $38.5 million. The company significantly increased its debt position with a new $72.9 million term loan and higher revolving credit usage to fund operations and $49.3 million in share repurchases.
Intellia Therapeutics reported Q3 2026 financial results, highlighting the FDA's acceptance and Priority Review of the BLA for lonvo-z with a PDUFA date of March 10, 2027. The company completed enrollment in its MAGNITUDE-2 Phase 3 trial for ATTRv-PN and expects its current cash position to fund operations into 2028.
Counterparty
Regeneron Pharmaceuticals, Inc.
Term
Q3 2026
“This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead. We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy.”
John Leonard, M.D., Intellia President and Chief Executive Officer